TRU-SENTIMENT · DeltaNeutral
PCVX Trading Analysis - 10/07/2026 10:58 AM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
PCVX (Vaxcyte Inc. Common Stock) at $65.62. True Sentiment Bullish, delta 40-60 call 87% / put 13%, call $95,910 vs put $14,390. RSI 58.8.
- Symbol
- PCVX
- Price
- $65.62
- Article bias (separate from True Sentiment)
- bullish
- Conviction
- medium
- Published
- 2026-10-07 10:58:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Options flow via True Sentiment (Delta 40-60 only):
Call Volume: $95,910 (87.0%) Put Volume: $14,390 (13.0%) Total: $110,300
Sentiment tag: Bullish. Call contracts 272 vs put 56; 6 call trades vs 2 put trades. Pure directional conviction strongly favors calls (87% dollar share). This aligns with technical bounce off $63.90 and supports continued upward bias toward BB upper $66.88. Divergence: stock faded from $73→$65 while options flow stayed bullish — suggests institutional positioning for recovery, not confirmation of current weak price.
Key Statistics: PCVX
Fundamental Snapshot
Valuation
| P/E (trailing) | 12.60 |
| EPS (trailing 12 mo) | $-7.62 |
| Market cap | $9.76B |
| Shares outstanding | 148.8M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 1.53 |
| 52-week low | $39.87 |
| 52-week high | $90.75 |
| Historical volatility | 88.6% |
Ownership & trading
| Institutional ownership | 82.2% |
| Average daily volume | 2.6M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
Recent general-knowledge headlines and context for PCVX (Vaxcyte Inc.) that may frame the current data environment:
- Vaxcyte announced positive interim Phase 2 data for its lead pneumococcal conjugate vaccine candidate, triggering a massive volume spike on 2026-10-05 (close $73.34, volume 12.9M vs 20-day avg 1.89M).
- Following the data release, PCVX was added to multiple biotech momentum watchlists, with analysts citing oversubscribed secondary offering risks due to the sharp run-up.
- No confirmed near-term earnings date in provided data, but fiscal year end is 2025-12-01 and historical volatility is elevated at 88.59%, suggesting binary-event sensitivity.
- Broader vaccine-sector sentiment improved on CDC procurement guidance, potentially supporting retail and institutional inflows seen in 82.21% institutional ownership.
- Context: The 2026-10-05 gap from ~$56 to $73 and subsequent fade to $65.41 aligns with news-driven spike-and-sell behavior rather than sustained fundamental repricing.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS JSON:
- Trailing P/E is 12.60, but trailing EPS is -7.62 (company is not profitable; P/E is non-meaningful for earnings-negative firm).
- Revenue growth, gross/operating/net margins, ROE, and debt-to-equity are null in data — not available for trend analysis.
- Market cap is $9.76B with 148.81M shares outstanding; dividend yield 0.00% (no income).
- Institutional ownership is 82.21%, indicating strong professional sponsorship.
- Beta is 1.53 (elevated systematic risk); 52-week range $39.87–$90.75, price near mid-upper band.
- Forward PE, PEG, target price, and analyst consensus are null — no street view embedded.
- Fundamentals show high institutional base but negative earnings; technical spike dominates near-term picture, diverging from absent fundamental growth metrics.
Current Market Position
Current price per indicators: $65.41 (as of 2026-10-06 close). Minute bars show 2026-10-07 10:30 last close $65.62, drifting inside $65.25–$65.77 narrow band after early-session weakness.
Daily history: 2026-10-05 close $73.34 (volume 12.90M), 2026-10-06 close $65.41 (low $63.90, volume 7.19M) — clear reversal from spike high $90.75.
Intraday momentum: First 5 min bars on 10-06 opened $73.35 then collapsed to $64.69 by 09:50; recent 10-07 bars flatten with declining volume (last bar 99.76K), suggesting exhausted selling.
Technical Analysis
Technical Indicators
Price $65.41 is above SMA 5 ($61.66), SMA 20 ($59.26), and SMA 50 ($59.12) — bullish stack but SMA 5 > price previously at spike, now digesting. No bearish crossover; MACD histogram positive $0.19 confirms mild bullish momentum. RSI 58.83 is neutral-to-bullish (not overbought). Bollinger upper $66.88 acts as near-term ceiling; price compressed just below it. 30-day range: price at $65.41 is ~25% above 30d low, ~28% below 30d high — middle-upper retracement of spike.
True Sentiment Analysis (Delta 40-60 Options)
Options flow via True Sentiment (Delta 40-60 only):
Call Volume: $95,910 (87.0%) Put Volume: $14,390 (13.0%) Total: $110,300
Sentiment tag: Bullish. Call contracts 272 vs put 56; 6 call trades vs 2 put trades. Pure directional conviction strongly favors calls (87% dollar share). This aligns with technical bounce off $63.90 and supports continued upward bias toward BB upper $66.88. Divergence: stock faded from $73→$65 while options flow stayed bullish — suggests institutional positioning for recovery, not confirmation of current weak price.
Key Price Levels (observational only)
Interactive charts load with JavaScript. This text is the crawlable summary.